ASIC Channels and Migraine Disease - Proof-of-Concept Study on the Efficacy of Amiloride in Migraine Aura Prophylaxis

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516044-25-00

Acronym

16-API-01

Enrollment

Registered

2024-10-17

Start date

2025-02-13

Completion date

Unknown

Last updated

2025-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraines with aura

Brief summary

Number of seizures with aura, with or without headache

Detailed description

Number of days with migraine headache, with or without aura, Number of days with any type of headache, with or without aura, Functional impact (impact score on HIT-6 scale), Emotional impact (anxiety and depression score on the HAD scale), Health status (EQ-5D scale score), Occurrence or absence of significant or unknown adverse events

Interventions

DRUGTablets for oral use

DRUGMODAMIDE 5 mg

DRUGcomprimé

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of seizures with aura, with or without headache	—

Secondary

Measure	Time frame
Number of days with migraine headache, with or without aura, Number of days with any type of headache, with or without aura, Functional impact (impact score on HIT-6 scale), Emotional impact (anxiety and depression score on the HAD scale), Health status (EQ-5D scale score), Occurrence or absence of significant or unknown adverse events	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026